BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, announced that its strategic distribution and licensing agreement with Electrome Corporation has officially moved into the execution phase. Manufacturing is now underway for the launch of BioElectronics’ flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform. This partnership marks a major milestone as Electrome prepares for an aggressive consumer launch strategy designed to accelerate awareness and adoption of BioElectronics’ drug-free pain therapy technologies across North America.
Electrome is currently building a comprehensive AI-native pain management platform that integrates advanced artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. The platform is designed to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions. Under the agreement, Electrome will market and distribute BioElectronics’ FDA-cleared pulsed shortwave therapy products, including ActiPatch and additional products within the BioElectronics portfolio.
“We are excited to officially begin the commercial phase of this relationship with Electrome,” said Kelly Whelan, President of BioElectronics Corporation. “The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth.”
Electrome’s planned rollout will focus heavily on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems designed to streamline the consumer purchasing experience while increasing awareness of non-drug pain management solutions. Ken Mayer, CEO of Electrome Corporation, commented: “This is an exciting moment for both organizations. We believe BioElectronics’ technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption.”
BioElectronics’ pulsed shortwave therapy technology is designed to provide drug-free, non-invasive pain relief through a wearable therapy platform cleared by the U.S. FDA for the adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures. Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.
BioElectronics Corporation is a medical device company focused on the development and commercialization of advanced bioelectronic therapies utilizing pulsed shortwave therapy technology for pain management and recovery applications. The company’s product portfolio includes ActiPatch, RecoveryRx, and RecoveryRx Veterinary. Electrome Corporation (https://electrome.com/) is a technology-enabled healthcare commercialization company focused on leveraging AI-driven systems, digital marketing, and advanced ecommerce infrastructure to scale innovative healthcare and wellness products in the direct-to-consumer marketplace.
This announcement is important because it signals the transition from agreement to execution for a partnership that aims to disrupt the pain management market by combining FDA-cleared, drug-free technology with AI-powered marketing and ecommerce. The success of this rollout could accelerate consumer adoption of non-pharmaceutical pain relief options, potentially reducing reliance on opioids and other drugs.
